Drug Trial Radar · NCT05568225
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Nov 15, 2022
Primary completion
Jul 15, 2024
Study completion Jul 15, 2024
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
Conditions
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
EtavopivatDrug
400 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat TreatmentTime frame: From Baseline to Week 24
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
University of Miami Hospital and Clinics
Miami, Florida
Ocala Oncology
Ocala, Florida
NYU Langone Health
New York, New York
Columbia University Irving Medical Center
New York, New York
University of British Columbia - St. Paul's Hospital
Vancouver, British Columbia, Canada
Hopital Saint Louis
Paris, France
Nice University Hospital - Hôpital de l'Archet
Route de Saint-Antoine, Nice, France
Universitoetsklinikum Heidelberg
Heidelberg, Germany
Universitaetsklinikum Muenster
Münster, Germany
Universitoetsklinikum Halle (Saale)
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.